Articles tagged with Breast Cancer
Researchers identified a cholesterol metabolite called hydroxycholesterol that suppresses the immune system's ability to attack cancer, leading to increased metastasis. The team discovered a line of communication used by immune cells and cancer cells that stimulates breast cancer progression.
Researchers at the University of Notre Dame developed a modular, computational pipeline to predict pH-sensitive protein structures. The new process enables screening hundreds of proteins in a few days, which can help design treatments for diseases like cancer, Alzheimer's, and Huntington's.
Researchers found that the leptin-SCD pathway fuels breast cancer growth and motility, leading to poorer recurrence-free survival. Selectively blocking SCD activity can counteract pro-tumorigenic effects driven by leptin, revealing a potential therapeutic target for obese patients.
Experts warn that new drugs for advanced breast cancer are unaffordable and may lead to unequal treatment access worldwide. The consensus panel recommended prioritizing most effective treatments and using next-generation sequencing for personalized medicine.
A new radioimmunotherapy approach has been developed to treat HER2-positive breast cancer, resulting in complete and histologic cures with minimal toxicities. The treatment uses a pretargeted approach to directly target tumors, reducing the risk of radiation toxicity to healthy tissues.
Researchers at OHSU develop a promising drug SU212 to treat intractable cases of triple-negative breast cancer. The molecule binds to and degrades the enzyme enolase 1, suppressing tumor growth and metastasis in humanized mouse models.
Triple-negative breast cancer often responds well to treatment, but 'persister' cells can reform a tumour, leading to relapse. A shared transcriptional programme determines which genes are active or not, with the FOSL1 protein playing a central role in resistance.
The study found that a nine-month programme of supervised exercise improved muscle mass and strength, particularly in the arms and legs, and physical performance in patients with breast cancer that had spread to other parts of the body. Muscle mass increased by an average of 0.79 kg after three months and 0.32 kg after six months compa...
Researchers at University of Miami Miller School of Medicine have developed a new combination therapy that shrinks tumors, reduces cancer stem cells and reprograms immune environment to combat hormone-resistant breast cancer. The triple therapy approach targets tumor-associated macrophages, which act like bodyguards for cancer cells.
A new case report describes the successful treatment of a 37-year-old woman with HER2-positive breast cancer that had spread to the membranes surrounding the brain and spinal cord. Trastuzumab deruxtecan, an antibody-drug conjugate, improved the patient's neurological symptoms and reduced cancer growth.
A new study found that patients with early-stage breast cancer who underwent a mastectomy and anti-cancer drugs had similar 10-year survival rates whether or not they received chest wall radiotherapy. The research team concludes that radiotherapy may no longer be necessary for these patients, reducing treatment burden and potential sid...
A global survey of nearly 4,000 young women with advanced breast cancer found that nearly half have children under 18 and face significant hardship. The study also revealed delays in seeking care, unmet psychosocial needs, and limited access to precision diagnostics.
The ABC Global Decade Report 2015-2025 reveals significant advances in breast cancer care for some patients globally. However, persistent inequalities leave many behind. The report's findings drive the creation of the ABC Global Charter 2025-2035, aiming to improve equitable progress and transform care for everyone with ABC.
A study of over 60,000 US patients with advanced breast cancer found average survival times increased by six to seven months since 2011. Researchers attribute the improvement to more effective treatments, wider diagnosis, and quality of care advancements.
A new editorial highlights the importance of primary care in preventing heart disease in breast cancer survivors. The study found that most women do not go on to develop serious cardiac disease, but those with higher-risk chemotherapy, older age, or multiple cardiovascular risk factors may benefit from closer monitoring.
A large global study of 23,000 people found that proton pump inhibitors (PPIs) used for indigestion and heartburn were associated with poorer overall survival and a higher risk of severe side effects in patients with breast cancer. Statins and metformin showed no significant impact on either survival or adverse events.
Researchers developed nanomachines that can function stably within living organisms, enabling starvation therapy to treat refractory pancreatic cancer. This approach improved treatment outcomes by depleting essential nutrients for cancer cell growth.
The DEFEND study aims to assess whether virtual exercise sessions can be successfully delivered to patients with cancer receiving chemotherapy. Researchers will evaluate the impact on physical function, fatigue, and disability.
Researchers outline biological mechanisms of breast cancer brain metastasis, highlighting key molecular pathways and the role of the brain microenvironment. The review also discusses emerging therapeutic approaches and calls for cross-disciplinary collaboration to improve outcomes.
A new study from Memorial Sloan Kettering Cancer Center identifies unique genetic signatures in cancer patients of non-European ancestry and finds adding immunotherapy can boost effectiveness for hard-to-treat follicular lymphomas. Additionally, researchers discover a web-based system to report head-and-neck cancer concerns, leading to...
A new Swedish study found that breast cancer risk varies depending on the type of hormone in hormonal contraceptives. Desogestrel was linked to a higher risk, while levonorgestrel products showed a lower risk, indicating that some contraceptives may be safer options for women with a higher baseline risk.
A new study suggests that collecting and testing cancer cells in patients' blood could help doctors choose the right breast cancer treatment. The 'labyrinth chip' technology separates cancer cells from other blood cells, allowing researchers to identify biomarkers that distinguish aggressive treatments from less invasive ones.
Researchers developed an AI tool to identify women at higher risk of developing interval breast cancers, which have a worse prognosis. The tool predicted 42.4% of interval cancers for women with the top 20% scores, suggesting it could optimize breast cancer screening programs by identifying those who need supplemental imaging.
A multiyear analysis of over 400,000 women and 28,000 breast cancer cases found a strong association between outdoor air pollution and increased breast cancer incidence. The study suggests that reducing car traffic and promoting alternative transportation can help mitigate this risk.
Recent discoveries in breast cancer biology highlight the potential of targeted therapies and molecularly guided treatment approaches. The review discusses various treatments, including monoclonal antibodies and immunotherapies, as well as challenges in treating triple-negative and HER2-positive breast cancers.
A new study led by Mayo Clinic researchers found that abemaciclib improves survival for people with high-risk, early-stage breast cancer. The drug reduced the risk of death by 15.8% compared to endocrine therapy alone among patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer.
Scientists at King's College London have developed a potential antibody therapy strategy that restricts the growth of treatment-resistant breast cancers. The 'triple-engineered antibody' harnesses the body's immune defences to attack tumour cells and activates immune cells to kill cancer cells.
A new study led by Silent Spring Institute examines how job-related chemical exposures contribute to breast cancer risk among foreign-born workers. Immigrant women are overrepresented in high-risk jobs with fewer health and safety protections, facing unique barriers to avoiding toxic exposures at work.
Researchers at the Mayo Clinic have found that platelet-rich plasma (PRP) treatment can significantly improve genitourinary syndrome of menopause (GSM) symptoms in breast cancer survivors. After six months, GSM symptoms such as sexual function, urinary symptoms and quality of life improved, even among those taking estrogen blockers.
Researchers at UCLA have developed CAR-NKT cell therapy, which can attack tumors from multiple fronts while dismantling their protective shields. The therapy uses engineered immune cells that can be mass-produced from donated blood stem cells and stored ready-to-use, offering a potentially life-changing treatment option.
A major study of breast, cervical, and ovarian cancers found significant inequalities in global care, with many low- and middle-income countries (LMICs) diagnosing cancer at a later stage. Surgery was offered consistently, but treatment consistency varied, with LMICs often choosing mastectomy over breast-conserving surgery.
Biologists at Cold Spring Harbor Laboratory have made a significant discovery that could lead to better patient outcomes for ER+ breast cancer patients. Inhibiting the BPTF protein in mice can slow cancer metastasis and restore tumors' susceptibility to hormone therapy, offering new hope for treating resistant forms of the disease.
A new antibody drug conjugate (ADC) sacituzumab govitecan has been shown to improve progression-free survival in patients with advanced triple-negative breast cancer who are ineligible for immune checkpoint inhibitors. The ADC targets the protein Trop2 on TNBC cells and delivers a potent chemotherapy drug directly to tumor sites.
A new class of anti-cancer agents—antibody-drug conjugates (ADCs)—has unveiled compelling evidence that can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer. The phase III DESTINY-Breast05 and DESTINY-Breast11 trials have shown superior efficacy and improved disease-free survival rates, positionin...
A phase 3 study found that giredestrant plus everolimus significantly improved progression-free survival in patients with ER-positive, HER-2-negative advanced breast cancer. The treatment combination reduced the risk of disease progression or death by 63% in patients with ESR1 mutations.
The study reveals geographic clusters of high and low screening for breast, cervical, and colorectal cancers in the US Northeast and Southwest. Future studies could examine county-level healthcare access to optimize cancer screening practices.
Recent studies from Sylvester have uncovered links between breast cancer, Superfund sites and social adversity. Researchers are also exploring the use of artificial intelligence (AI) in interpreting mammograms more accurately.
Researchers developed TAMENDOX to supplement (Z)-endoxifen in patients with CYP2D6 enzyme deficiency, improving drug concentration and effectiveness. The new therapy was well-tolerated, showing promise as an alternative to aromatase inhibitors for premenopausal women.
Researchers at MD Anderson have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer. The study also identifies a new biomarker for improved immunotherapy responses in solid tumors.
Researchers found high SIGLEC15 expression correlates with improved survival in breast cancer patients. SIGLEC15 suppresses EMT progression and metastatic potential by down-regulating ZEB1, N-cadherin, and vimentin levels. It also shows vulnerability to the MDM2 inhibitor Nutlin-3a, suggesting a potential therapeutic strategy.
A study by Huntsman Cancer Institute found that triple-negative breast cancer is fueled by lipids and that these fatty acids promote tumor growth. The research suggests that breast cancer patients and survivors with obesity could benefit from lipid-lowering therapies.
A cohort study reveals a significant association between social adversity and increased incidence of triple-negative breast cancer in Black women. The findings suggest potential social genomic and gene-environment interactions that contribute to disparities in breast cancer survival.
Prognosia, a biotech startup founded by WashU Medicine researchers, has been acquired by Lunit. The company's AI-based software analyzes mammograms to predict breast cancer risk, showing more than twice the accuracy of standard methods.
Dana-Farber researchers present promising phase 3 trial results for breast, lung, and bladder cancers, including improved quality of life for metastatic breast cancer patients. The trials also explore new approaches to kidney cancer treatment and real-world data analysis for metastatic breast cancer.
Researchers developed a latex-based tissue adhesive to prevent seroma formation and prolonged lymphorrhea after axillary dissection. The study found that the adhesive significantly reduced wound exudate volume and allowed patients to be discharged earlier, with no complications reported.
Women living close to Superfund sites in Florida face higher risks of developing aggressive breast cancers, including triple-negative subtype. A growing body of evidence suggests that environmental degradation and pollution are associated with poor health outcomes.
Researchers at UMass Amherst have developed a nanoparticle-based vaccine that prevents melanoma, pancreatic and triple-negative breast cancer in mice. The vaccine achieved remarkable survival rates, with up to 88% of vaccinated mice remaining tumor-free.
Researchers found that 27% of breast cancer cases have genetic features guiding personalized treatment immediately. The study identified over 8,300 cases suitable for future research, providing insights into prognosis and potential new treatments.
Research found that inflammatory markers are linked to different aspects of cancer-related fatigue, with some effects persisting after treatment. The study suggests targeting inflammation for developing treatments to alleviate this debilitating symptom.
The NCCN Guidelines Navigator now covers treatment for over a dozen cancer types, including hereditary risk assessment, providing seamless navigation and search capabilities. The new format aims to improve treatment decision-making based on the latest evidence and expert-consensus.
A new study shows that a multi-step effort to reduce unneeded pre-operative testing, using a tailored program for each hospital, can lead to significant reductions in wasteful tests. The findings have already spurred an expansion of the program to 16 more Michigan hospitals.
Women undergoing mastectomy may experience emotional and physical challenges, including worse psychosocial outcomes and a lack of standardized approach to assess quality of life. Researchers emphasize the importance of developing a validated screening tool to prepare women for surgery.
Researchers discovered that an enzyme called EZH2 drives triple negative breast cancer cells to divide abnormally, enabling them to spread. Inhibiting EZH2 with drugs like tazemetostat restored order to dividing cells and thwarted the spread of TNBC cells.
Researchers at Cold Spring Harbor Laboratory have created a tool called MaGNet to analyze the branching structure of mouse mammary glands. The system enables precise comparison of stained images and quantifies data with ease, allowing for earlier detection of breast cancer and investigation into hormonal changes and treatments.
A recent study published in Radiology found that adding molecular breast imaging to a 3D mammogram improved the ability to detect cancer in dense breast tissue. The combined test detected more cancerous tissue than either technique alone, increasing cancer finds by over double.
Researchers at King's College London have developed a genetic test that can predict which women with abnormal breast cells are most likely to develop invasive breast cancer. The test uses a genetic risk score to estimate a person's inherited likelihood of developing the disease, allowing for more personalized treatment options.
A polygenic risk score (PRS) can predict future breast cancer incidents in women diagnosed with ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS). PRS scores were associated with an increased risk of ipsilateral breast cancer, particularly in patients with a family history of breast cancer.
A groundbreaking study enrolls 465 AYA cancer patients to test if chatbot technology and digital education tools increase uptake of genetic counseling and improve patient outcomes. The trial aims to address longstanding gaps in genetic services for AYAs aged 18-39, who often receive care with limited access to genetic specialists.
The RadComp study found that both proton and photon radiation treatment options yielded excellent health-related quality of life (HRQOL) outcomes for women with non-metastatic breast cancer. The trial, which compared HRQOL tools, showed no significant differences between the two treatments at 6 months following treatment.
A phase III trial comparing proton and photon radiation therapy for breast cancer found that patients report equally strong health-related quality of life with either treatment. Patients treated with protons were more likely to say they would recommend or choose it again, but overall patient-reported outcomes were similar.